Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Luciano J. Costa, Suzanne R. Fanning, Joe Stephenson, Lawrence B. Afrin, Emily Kistner-Griffin, Tricia A. Bentz, Robert K. Stuart

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Ofatumumab is a fully human anti-CD20 monoclonal antibody with enhanced antibody dependent and complement dependent cytotoxicity. Lenalidomide induces T cell and natural killer (NK) cell activation and in vitro enhances clearance of chronic lymphocytic leukemia (CLL) cells by monoclonal antibodies. We performed a multi-center, phase 2 trial of sequential treatment with ofatumumab and lenalidomide in patients with advanced, relapsed and refractory (R/R) CLL, consisting of ofatumumab 2000 mg intravenously on day 1 and lenalidomide 10 mg on days 8-28, for up to six cycles. Twenty-one subjects were included with median age of 63 years and two prior lines of therapy. The overall response rate was 47.6% and 23.8% had stable disease. Median overall survival was 21.5 months. Neutropenia and thrombocytopenia were the most frequent adverse events. Tumor flare reaction occurred in 43% of subjects. Intracycle sequential ofatumumab plus lenalidomide is active in high-risk R/R CLL and well tolerated except for frequent cytopenias.

Original languageEnglish (US)
Pages (from-to)645-649
Number of pages5
JournalLeukemia and Lymphoma
Volume56
Issue number3
DOIs
StatePublished - Mar 1 2015

Keywords

  • Ofatumumab
  • chronic lymphocytic leukemia
  • clinical trial
  • lenalidomide
  • small lymphocytic lymphoma

Fingerprint Dive into the research topics of 'Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma'. Together they form a unique fingerprint.

Cite this